Positive results from NovoTTF Therapy registry data treating Brain Cancer - Novocure

Novocure has announced subgroup survival data from its US commercial patient registry, called PRiDe, which includes data from every recurrent Glioblastoma patient treated with NovoTTF Therapy from October 2011 through November 2013 at 91 leading oncology centers in the United States (n=457). PRiDe subgroup analyses demonstrate that recurrent Glioblastoma patients treated with NovoTTF Therapy in the real-world setting at first or second recurrence experienced a significantly longer median overall survival (OS) compared to patients treated at third or subsequent recurrences (median OS of 20.0 months and 8.5 months compared to 4.9 months).

In addition, the median survival of bevacizumab-naive recurrent Glioblastoma patients treated with NovoTTF Therapy was significantly longer compared to recurrent Glioblastoma patients treated with bevacizumab prior to receiving NovoTTF Therapy (median OS 13.4 months versus 7.2 months). Data will be presented at the 16th Biennial Canadian Neuro-Oncology Meeting.